Yaz, Yazmin, Beyaz and Ocella Increases Risk of Blood Clots Three-fold, Say New Studies

By Rheingold Giuffra Ruffo & Plotkin LLP

The FDA announced Tuesday that it is in the process of reviewing and finalizing the results of a study on the health risks associated with drospirenone, a main active ingredient in many birth-control pills including, Yaz, Yazmin, Beyaz and Ocella. This comes in response to two new studies published last month in the British Journal of Medicine that claim women taking oral contraceptives containing drospirenone are at a 2 to 3 times greater risk of developing blood clots than those who take oral contraceptives that contain levonorgestrel. The European Medicines Agency has already stated that the product labels of birth-control pills containing drospirenone will be updated to include this new information. Bayer, the parent company of Yaz, continues to stand by their assessment of the risks, saying “Bayer’s analysis of the overall body of available scientific evidence continues to support its current assessment about the safety of its oral contraceptives.”

The pills have been the focus of numerous lawsuits, many of which have be filed in New Jersey state court and consolidated before Judge Martinotti in Bergen County. Our firm has filed many suits on behalf of women who suffered injuries and even death from injuries caused by blood clots, most of which are before Judge Martinotti. Thankfully, he is expeditiously moving the docket toward trials.

If you have been injured as a result of taking Yaz, Yazmin, Beyaz or Ocella, contact the attorneys at Rheingold, Giuffra, Ruffo & Plotkin LLP to speak with an experienced drug liability attorney.

Related Posts

What Is Autism?

Recent studies show that Tylenol is related to autism diagnosis in adolescents. These studies have brought about new litigation involving Tylenol and acetaminophen and its alleged effects

View Article